Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors.

Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T.

ChemMedChem. 2011 Apr 4;6(4):623-7. doi: 10.1002/cmdc.201000541. No abstract available.

2.

Synthesis, characterization, and biological evaluation of (99m) Tc(CO)3 -labeled peptides for potential use as tumor targeted radiopharmaceuticals.

Baishya R, Nayak DK, Chatterjee N, Halder KK, Karmakar S, Debnath MC.

Chem Biol Drug Des. 2014 Jan;83(1):58-70. doi: 10.1111/cbdd.12166.

PMID:
23679852
3.

Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands.

DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR, Howard MJ, Marshall JF.

J Biol Chem. 2007 Mar 30;282(13):9657-65.

4.

A concise review of current radiopharmaceuticals in tumor angiogenesis imaging.

Lu X, Wang RF.

Curr Pharm Des. 2012;18(8):1032-40. Review.

PMID:
22272823
5.
6.

Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.

Yang J, Guo H, Miao Y.

Nucl Med Biol. 2010 Nov;37(8):873-83. doi: 10.1016/j.nucmedbio.2010.05.006.

7.

Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-triggered nanoaggregation probe.

Shen B, Jeon J, Palner M, Ye D, Shuhendler A, Chin FT, Rao J.

Angew Chem Int Ed Engl. 2013 Sep 27;52(40):10511-4. doi: 10.1002/anie.201303422.

8.

Biologically active Arg-Gly-Asp oligopeptides assume a type II beta-turn in solution.

Johnson WC Jr, Pagano TG, Basson CT, Madri JA, Gooley P, Armitage IM.

Biochemistry. 1993 Jan 12;32(1):268-73.

PMID:
8418846
9.

Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.

Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S.

Bioconjug Chem. 2009 Apr;20(4):750-9. doi: 10.1021/bc800455p.

10.

Evaluation of a novel Arg-Gly-Asp-conjugated α-melanocyte stimulating hormone hybrid peptide for potential melanoma therapy.

Yang J, Guo H, Gallazzi F, Berwick M, Padilla RS, Miao Y.

Bioconjug Chem. 2009 Aug 19;20(8):1634-42. doi: 10.1021/bc9001954.

11.

Cell-attachment activities of surface immobilized oligopeptides RGD, RGDS, RGDV, RGDT, and YIGSR toward five cell lines.

Hirano Y, Okuno M, Hayashi T, Goto K, Nakajima A.

J Biomater Sci Polym Ed. 1993;4(3):235-43.

PMID:
8476793
12.

Radiolabeled RGD peptides as integrin alpha(v)beta3-targeted PET tracers.

Tateishi U, Oka T, Inoue T.

Curr Med Chem. 2012;19(20):3301-9. Review.

PMID:
22664242
13.

Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1.

Aumailley M, Gurrath M, Müller G, Calvete J, Timpl R, Kessler H.

FEBS Lett. 1991 Oct 7;291(1):50-4.

14.

Liposomalized oligopeptides in cancer therapy.

Asai T, Oku N.

Methods Enzymol. 2005;391:163-76.

PMID:
15721380
15.
16.

Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules.

Saiki I, Iida J, Murata J, Ogawa R, Nishi N, Sugimura K, Tokura S, Azuma I.

Cancer Res. 1989 Jul 15;49(14):3815-22.

17.

Immunosuppressory activity of the cyclodimeric peptide with RGD-sequences.

Szewczuk Z, Buczek P, Stefanowicz P, Krajewski K, Wieczorek Z, Siemion IZ.

Acta Biochim Pol. 2001;48(1):121-30.

18.

Evaluation of synthetic cell-penetrating peptides, Pro-rich peptide and octaargine derivatives, as adenovirus vector carrier.

Kida S, Eto Y, Yoshioka Y, Nakagawa S, Kawasaki K, Maeda M.

Protein Pept Lett. 2010 Feb;17(2):164-7.

PMID:
20214640
19.

Structural studies of two antiaggregant RGDW peptides by 1H and 13C NMR.

Kieffer B, Mer G, Mann A, Lefèvre JF.

Int J Pept Protein Res. 1994 Jul;44(1):70-9.

PMID:
7960407
20.

Peptides and pseudopeptides incorporating D-Phe-Pro-Arg and Arg-Gly-Asp lead sequences as potential antithrombotic agents.

Ilas J, Hudecz F, Süli-Vargha H, Kikelj D.

J Pept Sci. 2008 Aug;14(8):946-53. doi: 10.1002/psc.1030.

PMID:
18383437
Items per page

Supplemental Content

Support Center